BioGenes and Alphalyse Partner to Improve the Future of HCP Monitoring

Recently, BioGenes and Alphalyse, two companies that have been active in the field of Host Cell Protein ( HCP ) detection for many years, partnered up to offer their respective methods to biologics developers for optimal outcomes. While BioGenes specializes in the development of HCP ELISAs and related 2D gel analytics, Alphalyse is an expert in  coverage analysis by Liquid Chromatography (LC) - Mass Spectrometry (MS).
HCPs stem from the production cell line used for biological product manufacturing. Defined as process-related drug impurities, they can negatively influence a biological drug’s quality, safety, and efficacy . Naturally, the accurate detection of HCP impurities heavily depends on the establishment of reliable and robust methods for HCP measurement.
The HCP ELISA is the predominant assay for continuous HCP monitoring, and ELISA reagent characterization is vital for determining the assay’s suitability for HCP detection and quantification. The most important parameters are a sufficient total HCP coverage, the demonstration of HCP log reduction, and a high level of assay accuracy. As recommended by current guidelines, the coverage determination should be performed using orthogonal methods.

Combining HCP Experience and Knowledge

Biologics developers have an increasing need for simultaneous HCP measurement and identification to improve HCP risk assessment: the ELISA is used for antibody -dependent measurement, and LC-MS for HCP identification.
BioGenes and Alphalyse will provide their combined know-how and experience in the HCP field to support the combined use of their respective methods. The combination of BioGenes’ more than 20 years in HCP ELISA development and Alphalyse’s experience in LC-MS for HCP monitoring combined with the orthogonal methods IAC-2D DIGE and ELISA-MS for reagent characterization will enable a solid HCP surveillance strategy including quantification and identification of relevant HCPs.
For biologics developers, this means maximized certainty regarding HCP levels and improved HCP documentation for approval by regulatory entities.
"We are very pleased to be working with Alphalyse, and believe that we can achieve great results from a combined strategy," said Dr. Alexander Knoll, CEO of BioGenes. "Together, we can make it possible for customers to rely on orthogonal methods for their drug development and increase their chances for successful market authorization. At the same time, we will be able to improve drug efficacy, and thus patient safety."
"Both companies have been very successful with their respective approaches for years. In this respect, they complement each other very well," added Thomas Kofoed, CEO of Alphalyse. "It is exciting to see how the combination of both our methods will hopefully change the future of HCP monitoring and become the new standard in drug development processes.”